Chunghwa Chemical Synthesis & Biotech Co., Ltd. (TPE:1762)

Market Cap	2.22B
Revenue (ttm)	1.29B
Net Income (ttm)	19.80M
Shares Out	77.56M
EPS (ttm)	0.39
PE Ratio	74.11
Forward PE	n/a
Dividend	0.19 (0.66%)
Ex-Dividend Date	Jul 26, 2024

Volume	8,931
Average Volume	70,156
Open	28.65
Previous Close	28.65
Day's Range	28.65 - 28.95
52-Week Range	23.50 - 53.70
Beta	0.32
RSI	42.24
Earnings Date	May 12, 2025

About TPE:1762

Chunghwa Chemical Synthesis & Biotech Co., Ltd. engages in the research, development, manufacture, and sale of active pharmaceutical ingredients (APIs) in Taiwan and the United States. It offers API products, which include immunosuppressant, oncology, anti-virus, immunomodulating agents, and other products, as well as peptide drugs. The company also develops bulk pharmaceutical products, such as anti-anxiety agents, antidiabetics, laxatives, antifungals, antihistamines, antiseptics, antiulcerants, cardiovascular drugs, skeletal, muscle relaxant...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1964
• Employees: 198
• Stock Exchange: Taiwan Stock Exchange
• Ticker Symbol: 1762

Financial Performance

In 2024, TPE:1762's revenue was 1.35 billion, a decrease of -35.42% compared to the previous year's 2.09 billion. Earnings were 53.03 million, a decrease of -79.98%.